The Respiratory Syncytial Virus (RSV) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Respiratory Syncytial Virus (RSV) Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued products.

GlobalData tracks 184 drugs in development for Respiratory Syncytial Virus (RSV) Infections by 144 companies/universities/institutes. The top development phase for Respiratory Syncytial Virus (RSV) Infections is preclinical with 92 drugs in that stage. The Respiratory Syncytial Virus (RSV) Infections pipeline has 159 drugs in development by companies and 25 by universities/ institutes. Some of the companies in the Respiratory Syncytial Virus (RSV) Infections pipeline products market are: National Institute of Allergy and Infectious Diseases, Pfizer and Sanofi.

The key targets in the Respiratory Syncytial Virus (RSV) Infections pipeline products market include Respiratory Syncytial Virus Fusion Protein (RSV F Protein), Respiratory Syncytial Virus RNA Directed RNA Polymerase L (Large Structural Protein or Replicase or Transcriptase or mRNA Guanylyltransferase or GDP Polyribonucleotidyltransferase or L or EC 2.7.7.48 or EC 2.1.1.56 or EC 2.7.7.88), and Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G).

The key mechanisms of action in the Respiratory Syncytial Virus (RSV) Infections pipeline product include Respiratory Syncytial Virus Fusion Protein (RSV F Protein) Inhibitor with 23 drugs in Pre-Registration. The Respiratory Syncytial Virus (RSV) Infections pipeline products include nine routes of administration with the top ROA being Oral and 22 key molecule types in the Respiratory Syncytial Virus (RSV) Infections pipeline products market including Small Molecule, and Subunit Vaccine.

Respiratory Syncytial Virus (RSV) Infections overview

Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice.

For a complete picture of Respiratory Syncytial Virus (RSV) Infections’s pipeline drug market, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.